What is the fate of repeat biopsies after diagnosis of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation?

Yakup Bostanci*, Ender Ozdena, Yarkin Kamil Yakupoglua, Serdar Savascib, Ali Faik Yilmaza, Saban Sarikayaa

aDepartment of Urology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
bDepartment of Urology, Bayburt State Hospital, Bayburt, Turkey

ARTICLE INFO

ABSTRACT

In this study, we reviewed the outcomes of patients undergoing repeat biopsies, following initial diagnosis of high grade prostatic intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation (ASAP) and compared the pathological results to second biopsies due to increased PSA. We retrospectively assessed transrectal ultrasound guided prostate biopsy (TRUSBP) database at our institution between January 2003 and March 2011. Nonparametric tests and binary logistic regression analysis was performed. Among the 1451 TRUSBP taken, 30.4%, 6.4%, 4.7% were diagnosed as prostate carcinoma (PCa), HGPIN, ASAP, respectively. Among patients with HGPIN and ASAP, 68 patients and 48 patients with subsequent biopsies were selected. We also selected 128 patients with diagnosis of benign prostatic tissue (BPT) and subsequent biopsies due to increased PSA. After second biopsy, HGPIN and PCa reported in 29.4% and 20.6%, respectively in HGPIN group; ASAP and PCa was reported in 25% and 37.5%, respectively in ASAP group. Significant increase in PCa rate was reported on second biopsy in ASAP group when compares to HGPIN group (37.5% vs 20.6%, p=0.04) and BPT group (37.5% vs 18.8%, p=0.009). Overall, PCa was diagnosed in 26.5%, 45.8%, 18.8% in HGPIN, ASAP, BPT groups, respectively. Significant difference in PCa rate was detected only in ASAP group. PSAD has significant effects on PCa in all groups (p=0.001 and p=0.01, respectively). HGPIN is no longer associated with higher risk of cancer. Patients should be followed with yearly prostate specific antigen (PSA) and digital rectal examination (DRE). Repeat biopsy should be made as soon as feasible in patients with ASAP.


© 2013 OMU

1. Introduction

Atypical small acinar proliferation (ASAP) and high grade prostatic intraepithelial neoplasia (HGPIN) are two common findings observed on prostate biopsies. In 5 to 10% of biopsy cases does not reveal clearly benign or malignant findings but rather HGPIN and/or ASAP which are considered to be predictors of subsequent prostatic adenocarcinoma (Epstein and Herawi, 2006). Prostatic intraepithelial neoplasia (PIN) was first described by Bostwick and Brawer in 1987 and defines architecturally benign prostatic acini and ducts lined by atypical cells. Although these atypical cells share morphological, histochemical, immunohistochemical and genetic changes with cancer, PIN lacks invasion of the basement membrane of the prostatic glands. PIN is usually multifocal and can involve clusters of glandular structures.
Prostatic repeat biopsy is usually recommended following diagnosis of HGPIN or ASAP, although number of procedures remains still unclear. Knowing the rate of PCA diagnosis on repeat biopsies would aid primary treating physicians in the decision-making process for suspicious cases. For this purpose, we reviewed the outcomes of patients undergoing repeat biopsies, following initial diagnosis of HGPIN or ASAP and compared the pathological results to second biopsies due to increased prostate specific antigen (PSA).

2. Material and methods

We retrospectively assessed 1451 transrectal ultrasound guided prostate biopsy (TRUSBP) performed at our institution between January 2003 and March 2011, using an extended peripheral zone biopsy scheme. Indications for TRUSBP were: Abnormal digital rectal examination and/or a serum PSA over 2.5 ng/ml. This scheme was defined by 10 to 22 (mean 16.3) peripheral zone biopsy cores incorporating the lateral horn with transition zone biopsy.

None of these patients had previous prostate biopsies. All patients were thoroughly examined by transrectal ultrasound (TRUS) before biopsy and prostate volumes were calculated by using an ellipsoid prostate formula. All of the lesions detected by TRUS were noted. Local anesthesia of 5 cc lidocaine (1%) was applied to prostate apex and base. All of the patients were placed in the left lateral decubitus position and all were examined with no bowel preparation. We used an 18 G core biopsy needle mounted on a spring-loaded automatic biopsy gun. All of the patients underwent a 10-core biopsy protocol with additional one core from each suspicious area detected by TRUS. In repeat biopsies, additional transitional zone sampling was added on both lobes. All patients underwent the same biopsy protocol regardless of the prostate gland size. All of the patients tolerated the biopsy procedure well and none of the patients needed intravenous sedation or narcotic analgesics. All taken biopsy specimens were labeled according to their localizations on prostate from where the biopsy was obtained and submitted separately in 10% formalin-filled containers to the Department of Pathology of our University Hospital.

We retrospectively reviewed our database to obtain PSA level and PSA density (PSAD) at the time of biopsy, prostatic volume, patient age, digital rectal examination (DRE) or TRUS results, time to the repeat biopsy, and the location of the ASAP, HGPIN and PCa according to needle biopsy results. When patients with an initial diagnosis of HGPIN or ASAP underwent another biopsy, four diagnoses were made: benign tissue, ASAP, HGPIN, or PCa. When performing analyses that compared the group with cancer with that with no cancer, we combined benign tissue and ASAP or HGPIN in a no-cancer group.

Clinical data were analyzed with Chi-square tests and Kruskal-Wallis test; in addition to these, binary logistic regression was performed to identify any correlation between the rates of cancer detection on repeat biopsy with the previously mentioned variables, while controlling for potentially confounding factors.

3. Results

Among the 1451 prostate biopsies taken 441 (30.4%) were diagnosed as PCa, 93 (6.4%) as HGPIN and 68 (4.7%) as ASAP. Among patients with HGPIN and ASAP, 68 patients and 48 patients were selected with subsequent biopsies due to diagnosis of HGPIN and ASAP, respectively.

We also selected 128 patients with the diagnosis of benign prostatic tissue (BPT) after first biopsy and we performed the repeat biopsies due to increased PSA values to compare the results with HGPIN and ASAP groups. Patient characteristics according to the pathology report on first biopsy are showed as a table (Table 1).

| Table 1. Patient characteristics according to the pathology report on first biopsy |
|-------------------------------|-----------------|-----------------|-----------------|
|                             | HGPIN            | ASAP            | BPT             |
| Number                       | 68               | 48              | 128             |
| Age                          | 65.5±1.9         | 62.6±2.2        | 62±1.2          |
| PSA (ng/ml)                  | 10.3±1.3         | 9.5±1.1         | 10.6±0.8        |
| DRE positive (%)             | 23.5             | 33.3            | 34.1            |
| TRUS positive (%)            | 20.8             | 29.4            | 26              |
| Prostate vol (cc)            | 45±5             | 41.3±4.8        | 42.7±3.3        |
| PSAD (ng/ml/cc)              | 0.26±0.04        | 0.27±0.04       | 0.3±0.03        |
| TZ-PSAD (ng/ml/cc)           | 0.64±0.01        | 0.55±0.08       | 0.72±0.14       |
| F/T PSA (%)                  | 20.3±3.5         | 17±5.6          | 16.2±2          |
| Mean repeat biopses          | 1.36±0.18        | 1.37±0.12       | 1.99±0.09       |
| Weeks between biopses        | 17.7±4           | 14.6±3.8        | 21±4            |

Chi-square test and Kruskal-Wallis test were used for statistical analysis. *Significance between Benign and the other groups. There was no difference between HGPIN and ASAP groups.

In the HGPIN group, 68 patients underwent a second biopsy, whereas, 29 (42.6%), and 3 (4.4%) patients also underwent third, and fourth biopsies, respectively. Similarly, in the ASAP group, all 48 patients underwent a second biopsy, whereas 14 (29.2%), and 4 (8.3%) patients also underwent third, and fourth biopsies, respectively. In the BPT group, all 128 patients underwent a second biopsy, whereas 19 (14.8%) and 6 (4.6%) patients underwent the third and fourth biopsies, respectively. The distribution of the pathological results of patients who underwent repeat biopsies according to previous biopsies are showed as a table (Table 2).

After the second biopsy, diagnosis of HGPIN was confirmed in HGPIN group in 20 of 68 patients (29.4%), whereas BPT and PCa were reported in 31 of 68 patients.
Considering all patients, the results of binary logistic regression analysis showed that age of patient, PSA levels, and DRE or TRUS findings were not significant predictors of PCa. Only PSAD has significant effects for the detection of prostate cancer in all groups (p=0.001). When considering the HGPIN and ASAP groups separately, the only factor predictive of malignancy was PSAD in the binary logistic regression analysis (p=0.01, p=0.04 respectively). Receiver operating characteristics curves for PSAD was shown in (Fig. 1). The area under the curve for PSAD was 61.5% (p=0.007).

Considering that our PCa detection rate was 30.6% after first biopsy, in those patients with HGPIN and ASAP, second, third and fourth biopsy added further 2.2%, 0.4% and 0.1% PCa detection rate respectively.

4. Discussion

Significant advances have been achieved in the diagnosis of PCa with the introduction of PSA and prostate biopsy techniques. However, the histological diagnosis of PCa in biopsy specimens remains a challenge for pathologists. In the prostate biopsies performed for suspected PCa, positive results confirm the diagnosis; however, the suspicion of cancer remains with negative results. Moreover, the suspicion of cancer becomes more prominent if the results of the biopsy reveal HGPIN or ASAP (Koca et al., 2011).

HGPIN was considered as precursor of PCa and a predictor of PCa on subsequent biopsies, especially in the era of sextant biopsy and repeat biopsy has become a standard of care for HGPIN for almost a decade (Kronz et al., 2001; Moore et al., 2005). The incidence of HGPIN shows marked variation in the literature ranging from 0% to 24.6%; the mean reported incidence is 7.7% (median 5.2%) (Epstein and Herawi, 2006). In a study with a large, community based prostate biopsy population, the incidence of HGPIN was reported as 3.0% in 42,667 patients (Girasole et al., 2006). In our series, the incidence was 6.4% and within the reported range. The false-negative rates of the sextant biopsy scheme became apparent after the standard practice has shifted to a more extensive sampling of the peripheral zone (Roehrborn et al., 1996; Fleshner et al., 1997). This shift has resulted in a nearly 30% increase in the cancer detection rate at initial biopsy (Babaian et al., 2000; Presti et al., 2000). However, the cancer detection rate on repeat biopsies in patients previously diagnosed with HGPIN is progressively decreasing with the increasing use of extended biopsy techniques (Eskew et al., 1997; Presti et al., 2000; Herawi et al., 2006). In a review by Epstein et al., the risk of cancer after a repeat biopsy for benign disease was 23% versus 18.7% for HGPIN (Epstein and Herawi, 2006). In this current study, risk of cancer after repeat biopsies in patients previously diagnosed with HGPIN is progressively decreasing with the increasing use of extended biopsy techniques (Eskew et al., 1997; Presti et al., 2000; Herawi et al., 2006). In a review by Epstein et al., the risk of cancer after a repeat biopsy for benign disease was 23% versus 18.7% for HGPIN (Epstein and Herawi, 2006). In this current study, risk of cancer after repeat biopsies for benign and HGPIN was 18.8% versus 26.5%, respectively. We did not observe significant differences between benign and HGPIN groups regarding PCa detection. Similarly, Naya et al. (2004) and Gallo et al. (2008) showed no statistical difference in the risk of cancer on repeat biopsy following a HGPIN diagnosis compared to repeat biopsy after a benign diagnosis. In addition, Lefkowitz et al. (2002) suggested that early repeat biopsy was not mandatory within the one year but approximately a quarter of men with HGPIN will have clinically detectable PCa during 3 years follow-up. So they recommended that all men with HGPIN undergo biopsy 3 years after diagnosis regardless of change in serum PSA. However there was no group of patients with benign diagnosis after first biopsy to compare to HGPIN regarding PCa during 3 years follow up. However, repeat biopsy should be performed if HGPIN is detected by a sextant biopsy technique, and if the biopsy has been performed with multiple sampling, other parameters, such as PSA or rectal...
examination status, should be considered (Moore et al., 2005
Epstein and Herawi, 2006; Eskcorapci et al., 2007; Orderda and Gontero, 2009). It is important to note that the detection of
PCa on repeat biopsies in patients with HGPIN detected in
their first biopsies is not a missed diagnosis in the initial biopsy,
but in fact might reflect the development of a new cancer
arising from HGPIN (Meng et al., 2003).
Increasing number of studies show that the number of
cores with HGPIN can help predict which patients are at
higher risk for cancer following a biopsy with the diagnosis
of HGPIN (Merrimes et al., 2011). Roscigno et al. (2004)
reported that cancer detection was significantly greater in
patients with plurifocal HGPIN than in those with monofocal
HGPIN (70% vs. 10%, respectively; P<0.005) (Roscigno et
al., 2004). Similarly Netto and Epstein (2006), Merrimen
et al., (2009) and De Nunzio et al. (2009) reported the
increased incidence of prostatic carcinoma on second biopsy in
patients with at least 4 cores involved with HGPIN defined
as widespread HGPIN. In our study, we observed that cancer
detection rate was significantly higher in patients with 2 cores
or more involved with HGPIN than in those with monofocal
HGPIN on second biopsy (36.6% vs. 11.1%, respectively;
P<0.01).
Like HGPIN, ASAP is also a rare isolated finding on ini-
tial needle biopsy. The 4.7% incidence of ASAP on initial bi-
opsy in our series is similar to the average rate of 5% reported
by Epstein and Herawi (2006). The average risk of cancer
following an atypical diagnosis is 40% on repeat biopsies so
a repeat biopsy is recommended to all patients with ASAP.
Iczkowski et al. (1998) reported the 295 patients with
ASAP, of whom 112 (38%) were diagnosed cancer on repeat
biopsy, 12 of the 36 (33%) patients on second repeat biopsy
and 1 of the 8 (12.5%) patients on third repeat biopsy. Thus
the nearly 85% of the cancer was diagnosed after first repeat
biopsy. Similarly, Moore et al. (2005) examined the 53 pa-
tients with ASAP in whom 85% of cancer was diagnosed on
first repeat biopsy. In our study, 18 of 22 (84%) cancer were
diagnosed on first repeat biopsy and 21 of 22 (94.5%) cancer
were diagnosed on second repeat biopsy in ASAP group.
Many investigators have attempted to determine clinical
and pathological predictors of cancer risk in patients with
ASAP and HGPIN. Some of them have noted no correla-
tion between patient age, DRE, TRUS findings, serum PSA
and cancer risk (Moore et al., 2005; Borboroglu et al., 2001;
Abouassaly et al., 2008). On the other hand, some authors not-
ed that age, PSAD, transitional zone PSA density (PSAD-TZ)
and the number of cores with HGPIN were found to predict
cancer in another series of HGPIN patients (Abdel-Khalek et
al., 2004; Eskcorapci et al., 2007). In this study, we found
that the only predictive factor for cancer was the PSAD in
both ASAP and HGPIN groups.
Several limitations should be considered when evaluating
the findings of this study. Data were collected retrospectively
from a database at a single tertiary care institution. So our
variables were obtained from clinical chart review they were
inherently incomplete. Biopsy samples were not examined by
the same pathologist, although all biopsies were examined in
the same pathology laboratory. The number of patients with
ASAP and HGPIN is relatively small, and this may increase
the possibility that our findings are due to chance.
In conclusion, ASAP and HGPIN entities have different
histological findings and more importantly for patient care
the finding of ASAP is associated with a much higher risk
of cancer on repeat biopsy compared to HGPIN and benign
groups. The finding of ASAP on prostate biopsy is associated
with an approximately 50% likelihood of underlying mali-
gnancy. In this selected group, 94.5% of cancer was diagnosed
on second repeat biopsy. Therefore, in these patients a re-
commendation of repeat biopsy should be made as soon as feasi-
ble. Further information is required for third repeat biopsy in
this selected group.

REFERENCES
intraepithelial neoplasia: A multivariate analysis model. BJU Int. 94, 528-533.
ma on saturation and traditional biopsies. J. Urol. 180, 911-914.
Bishara, T., Rammani, D., Epstein, J., 2004. High grade prostatic intraepithelial neoplasia on needle biopsy: Risk of cancer on repeat biopsy re-
lated to number of involved cores and morphologic pattern. Am. J. Surg. Pathol. 28, 629.
with previous benign sextant biopsies. J. Urol. 163, 158-162.
Borboroglu, P., Sur, R., Roberts, J., Amling, C., 2001. Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade
prostatic intraepithelial neoplasia on initial prostate needle biopsy. J. Urol. 166, 866-870.
Bostwick, D., Srigley, J., Grignon, D., Maksem, J., Humphrey, P., van der Kwast, T.H., Bose, D., Harrison, J., Young, R.H., 1993. Atypical ade-
nomatous hyperplasia of the prostate: Morphologic criteria for its distinction from well-differentiated carcinoma. Hum. Pathol. 24, 819-832.
prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. J. Urol. 181, 1069-1074.
Epstein, J.J., Herawi, M., 2006. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma:
Implications for patient care. J. Urol. 175, 820-834.
the prostate. J. Urol. 158, 505-508.


Herawi, M., Kahane, H., Cavallaro, C., Epstein, J., 2006. Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled. J. Urol. 175, 121-124.


